Norepinephrine transporter polymorphisms in Tourette syndrome with and without attention deficit hyperactivity disorder

No evidence for significant association

Christopher A. Rippel, Andrew J. Kobets, Dustin Y. Yoon, Phillip N. Williams, Yin Yao Shugart, Dana D. Bridges, David John Vandenbergh, Harvey S. Singer

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Noradrenergic abnormalities have been proposed in the pathophysiology of Tourette syndrome and attention-deficit hyperactivity disorder. Patients with Tourette syndrome with (n=115) and without (n=110) attention-deficit hyperactivity disorder were evaluated for association with two single nucleotide polymorphisms of the norepinephrine transporter gene (SLC6A2); a T-182C single nucleotide polymorphism located in the 5′ flanking promoter region and a silent mutation (G1287A) occurring in exon 9. A polymerase chain reaction restriction enzyme assay was developed for the T-182C single nucleotide polymorphism based on a prior sequencing methodology. In this case-control study, no association was identified between either polymorphism and Tourette syndrome or attention-deficit hyperactivity disorder. In a small subset, these NET polymorphisms did not predict therapeutic response to the noradrenergic transporter inhibitor atomoxetine. Further research with additional NET polymorphisms and larger sample sizes are indicated in the pursuit of biomarkers for therapeutic responders.

Original languageEnglish (US)
Pages (from-to)179-180
Number of pages2
JournalPsychiatric Genetics
Volume16
Issue number5
DOIs
StatePublished - Oct 1 2006

Fingerprint

Norepinephrine Plasma Membrane Transport Proteins
Tourette Syndrome
Attention Deficit Disorder with Hyperactivity
Single Nucleotide Polymorphism
5' Flanking Region
Enzyme Assays
Genetic Promoter Regions
Sample Size
Case-Control Studies
Exons
Biomarkers
Polymerase Chain Reaction
Therapeutics
Research
Genes

All Science Journal Classification (ASJC) codes

  • Genetics
  • Genetics(clinical)
  • Psychiatry and Mental health
  • Biological Psychiatry

Cite this

Rippel, Christopher A. ; Kobets, Andrew J. ; Yoon, Dustin Y. ; Williams, Phillip N. ; Shugart, Yin Yao ; Bridges, Dana D. ; Vandenbergh, David John ; Singer, Harvey S. / Norepinephrine transporter polymorphisms in Tourette syndrome with and without attention deficit hyperactivity disorder : No evidence for significant association. In: Psychiatric Genetics. 2006 ; Vol. 16, No. 5. pp. 179-180.
@article{69f9960fd96f4325b575af6d724ac5c8,
title = "Norepinephrine transporter polymorphisms in Tourette syndrome with and without attention deficit hyperactivity disorder: No evidence for significant association",
abstract = "Noradrenergic abnormalities have been proposed in the pathophysiology of Tourette syndrome and attention-deficit hyperactivity disorder. Patients with Tourette syndrome with (n=115) and without (n=110) attention-deficit hyperactivity disorder were evaluated for association with two single nucleotide polymorphisms of the norepinephrine transporter gene (SLC6A2); a T-182C single nucleotide polymorphism located in the 5′ flanking promoter region and a silent mutation (G1287A) occurring in exon 9. A polymerase chain reaction restriction enzyme assay was developed for the T-182C single nucleotide polymorphism based on a prior sequencing methodology. In this case-control study, no association was identified between either polymorphism and Tourette syndrome or attention-deficit hyperactivity disorder. In a small subset, these NET polymorphisms did not predict therapeutic response to the noradrenergic transporter inhibitor atomoxetine. Further research with additional NET polymorphisms and larger sample sizes are indicated in the pursuit of biomarkers for therapeutic responders.",
author = "Rippel, {Christopher A.} and Kobets, {Andrew J.} and Yoon, {Dustin Y.} and Williams, {Phillip N.} and Shugart, {Yin Yao} and Bridges, {Dana D.} and Vandenbergh, {David John} and Singer, {Harvey S.}",
year = "2006",
month = "10",
day = "1",
doi = "10.1097/01.ypg.0000218622.96127.71",
language = "English (US)",
volume = "16",
pages = "179--180",
journal = "Psychiatric Genetics",
issn = "0955-8829",
publisher = "Lippincott Williams and Wilkins",
number = "5",

}

Norepinephrine transporter polymorphisms in Tourette syndrome with and without attention deficit hyperactivity disorder : No evidence for significant association. / Rippel, Christopher A.; Kobets, Andrew J.; Yoon, Dustin Y.; Williams, Phillip N.; Shugart, Yin Yao; Bridges, Dana D.; Vandenbergh, David John; Singer, Harvey S.

In: Psychiatric Genetics, Vol. 16, No. 5, 01.10.2006, p. 179-180.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Norepinephrine transporter polymorphisms in Tourette syndrome with and without attention deficit hyperactivity disorder

T2 - No evidence for significant association

AU - Rippel, Christopher A.

AU - Kobets, Andrew J.

AU - Yoon, Dustin Y.

AU - Williams, Phillip N.

AU - Shugart, Yin Yao

AU - Bridges, Dana D.

AU - Vandenbergh, David John

AU - Singer, Harvey S.

PY - 2006/10/1

Y1 - 2006/10/1

N2 - Noradrenergic abnormalities have been proposed in the pathophysiology of Tourette syndrome and attention-deficit hyperactivity disorder. Patients with Tourette syndrome with (n=115) and without (n=110) attention-deficit hyperactivity disorder were evaluated for association with two single nucleotide polymorphisms of the norepinephrine transporter gene (SLC6A2); a T-182C single nucleotide polymorphism located in the 5′ flanking promoter region and a silent mutation (G1287A) occurring in exon 9. A polymerase chain reaction restriction enzyme assay was developed for the T-182C single nucleotide polymorphism based on a prior sequencing methodology. In this case-control study, no association was identified between either polymorphism and Tourette syndrome or attention-deficit hyperactivity disorder. In a small subset, these NET polymorphisms did not predict therapeutic response to the noradrenergic transporter inhibitor atomoxetine. Further research with additional NET polymorphisms and larger sample sizes are indicated in the pursuit of biomarkers for therapeutic responders.

AB - Noradrenergic abnormalities have been proposed in the pathophysiology of Tourette syndrome and attention-deficit hyperactivity disorder. Patients with Tourette syndrome with (n=115) and without (n=110) attention-deficit hyperactivity disorder were evaluated for association with two single nucleotide polymorphisms of the norepinephrine transporter gene (SLC6A2); a T-182C single nucleotide polymorphism located in the 5′ flanking promoter region and a silent mutation (G1287A) occurring in exon 9. A polymerase chain reaction restriction enzyme assay was developed for the T-182C single nucleotide polymorphism based on a prior sequencing methodology. In this case-control study, no association was identified between either polymorphism and Tourette syndrome or attention-deficit hyperactivity disorder. In a small subset, these NET polymorphisms did not predict therapeutic response to the noradrenergic transporter inhibitor atomoxetine. Further research with additional NET polymorphisms and larger sample sizes are indicated in the pursuit of biomarkers for therapeutic responders.

UR - http://www.scopus.com/inward/record.url?scp=33748754620&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33748754620&partnerID=8YFLogxK

U2 - 10.1097/01.ypg.0000218622.96127.71

DO - 10.1097/01.ypg.0000218622.96127.71

M3 - Article

VL - 16

SP - 179

EP - 180

JO - Psychiatric Genetics

JF - Psychiatric Genetics

SN - 0955-8829

IS - 5

ER -